Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. Earnings Recaps

AMPH Health Care 3 recaps
Q1 2026 May 12, 2026

Amphastar’s stock dropped sharply by 23.2% after earnings, reflecting investor disappointment over ongoing pricing pressure, rebate-related revenue headwinds, and mixed segment performance despite stable baseline business and pipeline progress.

Key takeaways
  • Net revenues reached approximately $171.2 million, driven primarily by recent product launches but offset by pricing pressure and product mix shifts in legacy products.
  • BAQSIMI revenue was about $32 million but impacted by higher rebates, channel mix, and greater government program utilization, masking an underlying 8% volume growth.
  • Primatene MIST generated roughly $30 million, with store-level sales up 6.5% year-over-year, supported by marketing efforts.
  • Pricing and competitive intensity remain variable and continue to pressure margins and top-line stability in legacy products.
  • The company’s pipeline shows progress with expected biosimilar and proprietary launches in 2027, though these have yet to meaningfully impact current financials.
Full recap
Q3 2025 Nov 10, 2025

Amphastar Pharmaceuticals reported solid third-quarter results, achieving net revenues of $191.8 million and a 14% year-over-year sales increase for BAQSIMI, while significantly expanding its proprietary pipeline.

Key takeaways
  • Q3 net revenues rose to $191.8 million, driven by strong performances in BAQSIMI and Primatene MIST.
  • BAQSIMI sales hit a record high of $53.6 million, an increase of 14% year-over-year, aided by enhanced sales execution.
  • The company secured U.S. and Canadian rights for three early-stage peptide candidates, broadening its pipeline with a market potential exceeding $60 billion.
  • FDA approval of iron sucrose injection (AMP-002) was achieved, contributing $2.4 million in sales during the quarter.
  • Amphastar is on track for multiple product launches in 2026 and 2027, positioning itself strategically in competitive therapeutic markets.
Full recap
Q2 2025 Aug 8, 2025

Amphastar Pharmaceuticals reported Q2 2025 net revenues of $174.4 million, driven by robust sales of BAQSIMI, which jumped 21% year-over-year, underscoring the strength of its diversified portfolio.

Key takeaways
  • BAQSIMI recorded its highest quarterly sales at $46.7 million, marking a 21% increase from the prior year.
  • Total revenues decreased 4% due to heightened competition in legacy products, yet steady performance in Primatene MIST indicated resilient consumer demand.
  • Amphastar announced a significant expansion of its California manufacturing facility, aimed at quadrupling domestic capacity to strengthen supply chain resilience.
  • The company remains optimistic about regulatory approvals, particularly for its AMP-002 and AMP-015 product candidates, with key GDUFA dates approaching.
  • Continued investment in R&D is a priority, with expenses rising 14% year-over-year to support future growth initiatives.
Full recap